Teva Pharmaceutical Industries Limited (TEVA)
| Market Cap | 32.65B |
| Revenue (ttm) | 16.78B |
| Net Income (ttm) | 713.00M |
| Shares Out | 1.15B |
| EPS (ttm) | 0.62 |
| PE Ratio | 46.12 |
| Forward PE | 11.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,510,442 |
| Open | 28.40 |
| Previous Close | 28.41 |
| Day's Range | 28.00 - 28.68 |
| 52-Week Range | 12.47 - 28.68 |
| Beta | 0.67 |
| Analysts | Strong Buy |
| Price Target | 27.00 (-5.13%) |
| Earnings Date | Nov 5, 2025 |
About TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
In 2024, Teva Pharmaceutical's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for TEVA stock is "Strong Buy." The 12-month stock price target is $27.0, which is a decrease of -5.13% from the latest price.
News
Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks
Druckenmiller invests his personal and family's wealth through his fund, the Duquesne Family Office. Druckenmiller is high on biotech stocks, with his top three holdings at the end of the third quarte...
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
TEL AVIV, Israel, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced that the European Comm...
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December
TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of execu...
Teva seeks startups to help solve global pharmaceutical challenges
Teva Pharmaceutical Industries said on Wednesday it was calling on startups to join its new platform to develop technologies to deal with a host of challenges facing Teva and the global pharmaceutical...
Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies London Healthcare Conference 2025 Transcript
Teva Pharmaceutical Industries Limited ( TEVA) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants Richard Francis - President, CEO & Director Conference Ca...
Generics Stalwart Teva Has Turned A Corner In Its Specialty Medicines Business
Generics Stalwart Teva Has Turned A Corner In Its Specialty Medicines Business
Billionaire Stanley Druckenmiller Sold His Fund's Entire Stakes in Nvidia and Palantir for a Scorching-Hot Drug Stock That's Up 218% Since Mid-2023
Quarterly-filed Form 13Fs can clue investors into which stocks and trends are piquing the interest of Wall Street's brightest money managers. Billionaire Stanley Druckenmiller dumped his fund's holdin...
Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript
Teva Pharmaceutical Industries Limited ( TEVA) UBS Global Healthcare Conference 2025 November 10, 2025 8:45 AM EST Company Participants Richard Francis - President, CEO & Director Conference Call Par...
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
PARSIPPANY, N.J., and TEL AVIV, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the prese...
Why Teva Pharmaceutical Stock Rocked the Market Today
The big drugmaker unveiled its latest set of quarterly figures. Thanks to healthy rises in sales of key drugs, its revenue and profitability rose admirably.
Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working
Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent quarter, what's driving growth, and much more.
Teva Pharmaceutical Industries Limited (TEVA) Q3 2025 Earnings Call Transcript
Teva Pharmaceutical Industries Limited ( TEVA) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Christopher Stevo - Senior Vice President of Investor Relations & Competitive In...
Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its third-quarter 2025 financial results on Wednesday, with total revenue of $4.48 billion, beating analysts' expectations of $4.35 billion, ac...
Teva Pharmaceuticals stock surges 12% as branded drug sales outperform
Teva Pharmaceutical Industries Ltd. stock rose 12% after the company reported stronger-than-expected third-quarter results, buoyed by robust growth in its branded drug portfolio.
Teva Pharm third-quarter profit tops estimates as branded drugs gain
Teva Pharmaceutical Industries reported on Wednesday a higher-than-expected rise in third-quarter profit, helped by strong sales of its trio branded drugs to treat migraines, Huntington's disease and ...
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
For an accessible version of this Press Release, please visit www.tevapharm.com Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dolla...
Here's Why This Israeli Investment Giant Is Betting $834 Million on Teva Stock
Israel-based Phoenix Financial acquired more than 3.5 million additional shares of Teva Pharmaceuticals for an estimated $62.1 million in the third quarter. Post-transaction, the fund reported holding...
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November
TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcom...
Blood pressure medicine recalled over high levels of cancer-causing chemical
More than half a million bottles of Prazosin Hydrochloride have been recalled over high levels of a chemical compound that could cause cancer, the FDA said.
Harel Bets Big on Teva Pharmaceutical by Purchasing 4.3 Million Shares
Added 4,306,363 Teva shares, an estimated $75.64 million trade based on the average quarterly price for Q3 2025 Transaction represents a 0.68% increase in reportable U.S. equity assets under managemen...
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
Teva and Prestige announce a license and supply agreement for the commercialization of Prestige's Tuznue ® , a biosimilar to Herceptin ® (trastuzumab) Tuznue ® received European Commission (EC) market...
Teva Vs. Viatris: Who Will Dominate In President Trump's America?
Teva Pharmaceuticals and Viatris occupy leading positions in the generic drugs market, valued at more than $613 billion in 2030. Each of them has advantages and "dark spots" in their portfolios of FDA...
Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026
Billionaire Stanley Druckenmiller has earned a spot among the best investors ever. Through more than four decades of investing, Druckenmiller has yet to post a year where his investments finished in t...
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (E...